Jam

ZenaTech (ZENA) qualifies under new Pentagon expedited drone procurement policy eliminating Green/Blue UAS certification requirements. Following a July 2025 directive reclassifying Group 1-2 drones as expendable assets, commanders can now directly purchase ZenaTech’s combat-ready portfolio (ZenaDrone 1000, IQ Square, IQ Nano) for training and missions. The policy mandates experimental unit adoption by September 2025, squad-level use in FY2026, and full DoD training integration by 2027. AI-enabled drone capabilities include operations in GPS-denied areas. While accelerating market access, the expendable classification may pressure pricing and invite competition.

Creative Medical Technology (CELZ) secured USPTO patent allowance through 2040 for its ImmCelz™ therapy targeting heart failure and post-heart attack damage. The treatment, delivered via minimally invasive outpatient procedure, addresses a potential US patient population exceeding 11 million. While this significantly broadens the company’s regenerative medicine IP portfolio, the therapy remains in development and lacks FDA approval or current revenue.

Milestone Pharmaceuticals announced an underwritten public offering of common shares with Series A and Series B warrants, plus pre-funded warrants for certain investors. Proceeds will primarily fund the clinical development and U.S. commercial launch of its PSVT treatment candidate, etripamil, while covering working capital. TD Cowen, Piper Sandler, and Wells Fargo Securities are joint bookrunners, with H.C. Wainwright as lead manager. This financing supports Milestone’s transition toward commercialization, though it may dilute existing shareholders.

XPENG launches G6 and G9 electric SUVs in Europe featuring ultra-fast charging capabilities. The G9 achieves 525 kW peak charging power while the G6 reaches 451 kW, enabling 10-80% charge in just 12 minutes. Both offer premium features: G9 provides up to 585 km WLTP range, G6 delivers 535 km. Utilizing 800V architecture with 5C Supercharging AI Battery technology and military-grade safety systems, the models incorporate Qualcomm Snapdragon 8295 and NVIDIA Orin-X processors for advanced autonomy. Available in eight European countries, deliveries begin late summer 2025.

Aker Solutions reported robust Q2/H1 2025 results. Q2 EBITDA margin was 8.3%, EPS NOK 1.46, net cash NOK 2.1bn, with order intake NOK 10.9bn and backlog NOK 68.0bn. H1 EPS was NOK 2.81. Revenue rose to NOK 15.2bn in Q2, driven by Life Cycle growth despite renewables margin pressure. The CEO highlighted project milestones and tech advances (e.g., autonomous drones). The company maintains its 2025 guidance: revenue exceeding NOK 55bn and underlying EBITDA margin (ex-OneSubsea) of 7.0-7.5%.

Civista Bancshares (NASDAQ: CIVB) priced an offering of 3.29 million common shares at $21.25 each, aiming to raise ~$70 million. With an underwriters’ option, proceeds could reach $80.5 million. The capital, expected to close July 14, will fund organic growth and potential acquisitions in Midwest markets. Piper Sandler leads the transaction under Civista’s existing SEC shelf registration.

Faraday Future launches its FX Super One MPV and AI tech on July 17th. Concurrently, verified FFAI shareholders (as of July 10, 2025) gain exclusive pre-ordering access and tiered perks via Stockperks. These include a $3,500 purchase voucher for Futurist tier holders (1+ shares) and extensive benefits like lifetime warranty/maintenance for Prestige holders (100,000+ shares), alongside priority delivery and customization. Targeted US deliveries start late 2025. (98 words)

South Bow (SOBO) will release Q2 2025 financial results after markets close on August 6, 2025. An earnings call follows on August 7th at 8:00 AM MT. The pure-play pipeline operator’s performance, particularly terminal utilization and tolling agreements, is watched amid sector scrutiny over regulations and volatile markets. Management will address operational efficiency, regulatory challenges, and commercial resilience of its key Alberta-U.S. crude oil network.

Shareholders of Till Capital approved Silver Storm Mining’s acquisition deal on July 10, 2025. The court-supervised transaction requires final approvals from the B.C. Supreme Court (hearing July 15) and TSX-V to close around July 17. This expands Silver Storm’s Mexican silver assets, primarily the past-producing La Parrilla Complex. Reactivating La Parrilla relies on historical data, not updated feasibility studies, increasing operational uncertainty. Completion remains contingent on court and exchange approvals.

SeaStar Medical raised $4M through a registered direct offering of 5.24 million shares priced at $0.763 each, with five-year warrants exercisable at $0.638. The capital infusion supports commercialization of its FDA-approved pediatric AKI device and adult trials, but triggers 33% equity dilution. Analysts note the structure creates potential stock price pressure, as warrants priced 16% below offering prices might constrain valuations. While addressing immediate liquidity needs, the conventional equity approach suggests urgency in funding operations rather than strategic growth initiatives, with funds allocated vaguely for corporate purposes.